Insulin-like Growth Factor 1

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone primarily produced in the liver and plays a crucial role in growth and development. Researchers primarily study IGF-1 for its involvement in various physiological processes, including glucose metabolism, muscle growth, and cardiovascular health. Key findings from recent studies indicate that IGF-1 signaling is linked to the regulation of glucose uptake in colorectal cancer and contributes to muscle hypertrophy by enhancing protein synthesis while inhibiting atrophy. Additionally, clinical evidence suggests that IGF-1 may play a protective role in cardiac adaptation to stress and reduce atherosclerosis in models of hypercholesterolemia. Current research continues to explore the multifaceted roles of IGF-1 in health and disease, highlighting its potential implications in therapeutic strategies.

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C and Mecasermin, is an endogenous peptide hormone primarily produced in the liver, although it is also synthesized in other tissues. It belongs to the growth factor category and shares structural similarity with insulin. IGF-1 plays a crucial role in growth and development, acting as a mediator of growth hormone (GH) effects. Researchers have extensively studied IGF-1 for its involvement in various physiological processes and diseases, including cancer, muscle hypertrophy, and cardiovascular health. IGF-1 is pivotal in regulating glucose metabolism, particularly in colorectal cancer, where it influences the Warburg effect. It also plays a significant role in skeletal muscle hypertrophy by modulating anabolic and catabolic pathways, and it has been observed to reduce coronary atherosclerosis in animal models. Mechanistically, IGF-1 exerts its effects through the IGF-1 receptor (IGF-1R), activating signaling pathways such as PI3K/Akt/mTOR and MAPK, which are involved in cell growth, survival, and metabolism. These pathways also intersect with glucose transport and glycolysis, impacting cancer cell metabolism and muscle protein synthesis. Pharmacokinetically, IGF-1 has a circulating half-life of approximately 12-15 hours when bound to its binding proteins, which extend its stability in the bloodstream. It is metabolized primarily in the liver and excreted by the kidneys. Clinically, IGF-1 is used in the treatment of growth failure in children with severe primary IGF-1 deficiency. It is regulated as a prescription medication and is prohibited in sports by the World Anti-Doping Agency due to its performance-enhancing potential.

IGF-1 acts primarily through the IGF-1 receptor (IGF-1R), triggering the PI3K/Akt/mTOR and MAPK signaling pathways. These pathways lead to increased protein synthesis, cell growth, and survival, while also modulating glucose metabolism and inhibiting apoptotic processes.

Insulin-like Growth Factor 1 (IGF-1) primarily acts through the IGF-1 receptor (IGF-1R), activating downstream signaling pathways such as the PI3K/Akt/mTOR and Raf/MAPK pathways. These pathways promote anabolic processes, including protein synthesis and glucose metabolism, while inhibiting catabolic processes like muscle atrophy through the suppression of FoxO transcription factors and E3 ubiquitin ligases. The precise mechanisms linking IGF-1 signaling to various biological processes, particularly in cancer metabolism and muscle regulation, remain incompletely understood.

Current evidence is limited regarding the specific mechanisms by which IGF-1 signaling interacts with metabolic syndrome and contributes to colorectal cancer progression, particularly in relation to the Warburg effect and the activation of key metabolic pathways. Further research is needed to explore the role of IGF-1 in muscle atrophy and hypertrophy across diverse chronic disease states, including the impact of miRNA regulation on IGF-1 signaling. Additionally, larger randomized controlled trials are necessary to evaluate the long-term effects of IGF-1 treatment on cardiovascular health and atherosclerosis in varied populations, particularly in those with pre-existing conditions like familial hypercholesterolemia.